Innoviva enters distribution, license agreement with Basilea for Zevtera

Innoviva (INVA) announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica for the commercialization of Zevtera, an advanced-generation cephalosporin antibiotic, in the United States. In April, the FDA approved Zevtera for three specific treatment indications, and it is the only FDA-approved methicillin-resistant Staphylococcus aureus, or MRSA, cephalosporin antibiotic for treating adult patients with Staphylococcus aureus bloodstream infections and endocarditis. Zevtera is indicated for the treatment of adult patients with SAB, including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.